Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists dive deep into Body's battle with COVID-19 and flu

NCT ID NCT05557539

Knowledge-focused Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study collected blood, urine, and nasal swab samples from 249 adults—some with COVID-19, some with the flu, and healthy controls—at two time points. Researchers used a systems biology approach to analyze the data, aiming to understand why people respond differently to these infections. The goal is to improve personalized care for future patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could help doctors better predict and personalize treatment for patients with COVID-19 or flu based on their unique biological responses.
What could go wrong
This is an observational study that only collected samples and analyzed data—it does not test any treatment. The findings may not lead to immediate clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

249 people

The number who actually took part.

Started

Feb 2022

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * For all: (1) 18 years or over; (2) Patient or legal representative have provided informed consent. * Cases: Reverse-transcriptase polymerase chain reaction (RT-PCR) confirmed symptomatic SARS-CoV-2 infection. * Controls : 1. Patient presenting with acute respiratory failure: (1) Patient presenting with hypoxemic respiratory failure diagnosed by the treating physician and influenza proven as the cause of the respiratory failure; (2) active SARS-CoV-2 infection excluded by RT-PCR and deemed non-probable by the treating physician. 2. Healthy controls : (1) Patients presenting without acute respiratory failure (ie. SpO2 \>93%); (2) no RT-PCR or antigen rapid test proven SARS-CoV-2 infection within the last 6 months; (3) no active respiratory tract infection. 3. Dexamethasone controls: Patient presenting to the day hospital for an upper or lower limb surgery and who will receive dexamethasone in this context. The criteria for healthy controls also apply. Exclusion Criteria: * For all: (1) \<18 years old ; (2)unwilling to provide informed consent; (3) pregnancy at the time of inclusion * For cases: Asymptomatic infection * For controls: 1. Active COVID-19 infection diagnosed by RT-PCR or suspect according to the treating physician at the time of inclusion, 2. For healthy controls: Acute or chronic respiratory failure. 3. Patient currently receiving dexamethasone (i.e. before study inclusion). The criteria for healthy controls also apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Influenza viral infections are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19 influenza

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Influenza viral infections SARS-CoV-2 infection

Contacts and locations

Locations

  • Cliniques Universitaires Saint-Luc

    Brussels, 1200, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.